Who is sponsoring NCT02125682?

NCT02125682 is sponsored by Hotel Dieu de France Hospital.

What drugs are being tested in NCT02125682?

Interventions in NCT02125682: atovastatin 10 mg/day, Atorvastatin 80 mg/day.

What condition does NCT02125682 study?

NCT02125682 studies Dyslipidemia in Patients With Diabetes Mellitus.

Is NCT02125682 still recruiting?

NCT02125682 is currently completed. Last updated 30 January 2018.

Last reviewed 2018-01-30 · How we verify

NCT02125682: HDL PROTECT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atorvastatin Action on Oxidative Stress and Inflammation in Type II Diabetes: The HDL Particle Protection Study

Completed Phase 4 Last updated 30 January 2018

What this trial tests

Phase 4 trial testing atovastatin 10 mg/day in Dyslipidemia in Patients With Diabetes Mellitus in 16 participants. Completed in 14 May 2017.

Timeline

1 January 2012

Primary endpoint
14 May 2017

14 May 2017

Quick facts

Lead sponsor	Hotel Dieu de France Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	16
Start date	1 January 2012
Primary completion	14 May 2017
Estimated completion	14 May 2017
Sites	1 location across Lebanon

Drugs / interventions tested

atovastatin 10 mg/day — full drug profile →
Atorvastatin 80 mg/day — full drug profile →

Conditions studied

Dyslipidemia in Patients With Diabetes Mellitus — all drugs for Dyslipidemia in Patients With Diabetes Mellitus →

Sponsor

Hotel Dieu de France Hospital

Who can join

Adults 21 to 80, any sex, with Dyslipidemia in Patients With Diabetes Mellitus.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

effect on HDL function
Time frame: 8 weeks
Does atorvastatin 80 mg/day improve HDL function more than 10 mg/day. HDL function will be assessed via several tests

Sponsor's own description

Atorvastatin is a statin that significantly decreases LDL level. At 10 mg/day, atorvastatin increases HDL level by 4-5%. At 80 mg/day, atorvastatin does not increase HDL level. However, atorvastatin is more protective at 80 mg/day than at 10 mg/day. This is due to a better reduction in LDL level at 80 mg, but we also think that 80 mg/day of atorvastatin is superior to 10 mg/day in improving the QUALITY of HDL, such as improving HDL particle number and function (better anti-oxydant activity)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hotel Dieu de France Hospital trials

Trials by the same sponsor.

NCT07292909 — Effect of Empagliflozin on Inflammation · Phase 4 · recruiting
NCT06917768 — Oral Corticosteroids' Role in Pediatric Obstructive Sleep Apnea · NA · completed
NCT03578042 — Fixed-Free HTN Trial · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02125682 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hotel Dieu de France Hospital
Last refreshed: 30 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02125682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing